Details of Disease

General Information of Disease (ID: DISAYSZB)

• Disease Name: Cutaneous T-cell lymphoma
• Synonyms: skin T-cell non-Hodgkin's lymphoma; primary cutaneous T-cell non-Hodgkin's lymphoma; primary cutaneous T-cell non-Hodgkin lymphoma; cutaneous T-cell non-Hodgkin's lymphoma; cutaneous T-cell non-Hodgkin lymphoma; cutaneous T-cell lymphoma; cutaneous T cell lymphoma; T-cell non-Hodgkin's lymphoma of the skin; T-cell non-Hodgkin's lymphoma of skin; PCTCL; CTCL
• Disease Class: 2B01: Mycosis fungoides
• Definition: A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.
• Disease Hierarchy:
  DISY0E8H: Primary cutaneous lymphoma
  DISAYSZB: Cutaneous T-cell lymphoma
• ICD Code:
  ICD-11: ICD-11: 2B01
  ICD-10: ICD-10: C84.0

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bexarotene	DMOBIKY	Approved	Small molecular drug	[1]
Methoxsalen	DME8FZ9	Approved	Small molecular drug	[2]
Mogamulizumab	DMISH0Z	Approved	Monoclonal antibody	[3]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[4]
Vorinostat	DMWMPD4	Approved	Small molecular drug	[5]

This Disease is Treated as An Indication in 17 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adcetris	DMEDF2B	Phase 3	NA	[6]
SGX301	DME2W98	Phase 3	NA	[7]
BNZ-1	DM8JQZC	Phase 2	Peptide	[8]
CD11301	DMRXJTP	Phase 2	NA	[3]
Cobomarsen	DMF4MX9	Phase 2	NA	[9]
Interleukin-12 gene therapy	DMPO5IC	Phase 2	NA	[10]
NM-IL-12	DMXNWZC	Phase 2	NA	[3]
Remetinostat	DMJIB89	Phase 2	NA	[3]
Resimmune	DMT5QSD	Phase 2	NA	[6]
Resiquimod	DML6XSP	Phase 2	Small molecular drug	[11]
RP6530	DMYILGK	Phase 2	NA	[3]
SHAPE	DMIQB13	Phase 2	NA	[7]
Forodesine	DME2W4T	Phase 1/2	Small molecular drug	[12]
BBI-3000	DMYDVY4	Phase 1	NA	[8]
CD7.CAR/28zeta CAR T cells	DMHTNLJ	Phase 1	CAR T Cell Therapy	[13]
Plasmid IL-12 immunotherapy	DMNMO8R	Phase 1	NA	[14]
WP1220	DM8RNSB	Phase 1	Small molecular drug	[15]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
D-4418	DMUPEJK	Discontinued in Phase 1	Small molecular drug	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6852).
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT03837457) PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM). U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of OncoSec Medical.
• [11] ClinicalTrials.gov (NCT03292406) A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL). U.S. National Institutes of Health.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8272).
• [13] ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
• [14] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals Inc.
• [15] ClinicalTrials.gov (NCT04702503) Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL). U.S. National Institutes of Health.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007757)